All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-08-07T14:42:30.000Z

SHIP: Red cell distribution width as a predictor of thromboembolic complications

Aug 7, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

Bookmark this article

Thromboembolic complications are a high risk for patients with myeloproliferative neoplasms (MPN), yet prognostic parameters for increased risk are currently lacking.1 Previously, a study identified risk factors for patients with polycythemia vera for clinical prediction of thromboembolic events.2

The MPN Hub has also reported on the risk of thrombosis in patients with secondary myelofibrosis.3 Below, the MPN Hub summarizes a new analysis investigating the predictive value of these parameters in a normal  (individuals without myeloproliferation or hematopoietic cancers) control population in order to validate these findings.1

Study design

This analysis was conducted in two independent cohorts of patients from the Study of Health in Pomerania (SHIP). In total, 2,491 patients were assessed between 1997 and 2001, and 4,358 patients were assessed between 2008 and 2011.1 Baseline characteristics of established risk factors for thromboembolic events are summarized in Table 1. Receiver operating characteristic curves were calculated to assess the predictive value of the model.1

Table 1. Baseline characteristics*

Baseline characteristic (%, unless otherwise stated)

SHIP-START-0

SHIP-TREND-0

Male

49.5

48.5

Age (range)

20–81

20–84

BMI (kg/m2)

27.1

27.5

Hypercholesterolemia

26.4

21.2

Hypertension

40.9

48.0

Diabetes mellitus

8.0

10.4

RDW

12.4

13.1

Hematocrit

39.9

41.8

BMI, body mass index; RDW, red cell distribution width; SHIP, Study of Health in Pomerania.
Adapted from Manz K, et al.1

 Results

In both cohorts, age, hypercholesterolemia and red cell distribution width (RDW) were identified as predictors of thromboembolic events.1 Thromboembolic events had occurred in 12.9% of individuals in the SHIP-START cohort and 21.4% of the SHIP-TREND cohort, and confirmed risk factors were as follows:1

  • In the SHIP-TREND cohort, increased age, hypercholesterolemia, and elevated body mass index scored as predictive factors for risk of thromboembolism (Figure 1A).
  • In the SHIP-START cohort, male sex and diabetes mellitus were also scored as predictive factors for risk of thromboembolism (Figure 1B).
  • In both cohorts, age, hypercholesterolemia, and RDW were confirmed as predictors of thromboembolic events.
  • RDW with an odds ratio of 1.28 (95% confidence interval [CI], 1.11–1.47) in the SHIP-START cohort and 1.25 (95% CI, 1.12–1.38) in the SHIP-TREND cohort.

Figure 1. A. SHIP-START-0 final model odds ratios. B. SHIP-TREND-0 final model odds ratios* 

*Adapted from Manz, et al.1
BMI, body mass index; CI, confidence interval; HCL, hypercholesterolemia; OR, odds ratio; PLT, platelet; RDW, red cell distribution width.

Conclusion

These results confirm that RDW could be used as an independent predictive parameter for thromboembolic evets in the general population.1 Further validation of predictive scoring systems combining predictive laboratory parameters are required, but this study confirms this would be worth investigating; with model accuracy rates of 89.2% and 86.8% for the SHIP-START and SHIP-TREND cohorts respectively.1

  1. Manz K, et al. Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: Analysis on 6849 participants of the SHIP-study. 2023. Online ahead of print. DOI: 10.1038/s41375-023-01943-8
  2. Verstovsek S, et al. US Optum Database Study in Polycythemia Vera Patients: thromboembolic events (TEs) with hydroxyurea (HU) vs ruxolitinib switch therapy and machine-learning model to predict incidence of TEs and HU failure. Blood. 2019;134:1659. DOI: 10.1182/blood-2019-126410
  3. Mora B, Guglielmelli P, Kuykendall A, et al. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study on 1258 patients. 2022;36(10):2453-2460. DOI: 10.1038/s41375-022-01673-3

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox